ELRIG’s meeting on Advances in Cell-based Screening 2022 takes place at AstraZeneca in Gothenburg, Sweden on May 10-12, 2022.
The meeting is bringing together leading scientists from academia, industry and the vendor community to share and discuss the latest advancements and best practices for the application of cell-based approaches in early drug discovery.
At the meeting, Åke Jägervall, Lab Manager at Cellectricon, is presenting a poster resulting from a collaboration with the Stanley Center for Psychiatric Research at the Broad Institute (Cambridge, MA, USA).
The poster is titled:
“A NaV1.2 modulator discovery program for treatment of SCN2A-related disorders such as autism spectrum disorder and intellectual disability”
During the collaboration, Cellectricon provided an integral part of the screening cascade by establishing a novel primary high-throughput screening (HTS) assay for NaV1.2 modulators and applying the assay for an HTS campaign to identify and validate small molecule enhancers of NaV1.2 function.
To receive a copy of the poster and to learn more about Cellectricon’s drug discovery services we invite you to reach out to us.
JENNIE SVENSSON DALÉN
DIRECTOR, MARKETING AND SALES
Want to learn more?
If you would like to learn more about Cellectricon’s neuroscience drug discovery services, you are very welcome to reach out and schedule a meeting with us.